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doi:10.1016/j.jfma.2011.09.003Background/Purpose: Microsomal epoxide hydrolase (EPHX) is an important enzyme that
metabolizes harmful reactive epoxides from smoking. Genetic variations of this enzyme are
thought to increase the risk of developing chronic obstructive pulmonary disease (COPD).
The aim of this study was to confirm and advance our knowledge of the role of this genetic vari-
ation in COPD. In addition, the association between this gene and important COPD-related
phenotype bronchodilator responses (BDRs) was studied.
Methods: This was a hospital-based caseecontrol study. The EPHX1 genetic mutations of 105
smokers with COPD and 103 control smokers without COPD were evaluated by polymerase
chain reaction, followed by restriction fragment length polymorphism analysis. The association
of genetic mutations and COPD phenotypes was also studied.
Results: Subjects with EPHX1 113 (His113/His113) homozygote mutation had a strong correlation
with COPD (odds ratio: 2.7, 95% confidence interval: 1.5e5.2). In addition, compared with
other genotypes, the His113 homozygote mutation patients had significantly lower BDRs, as
shown by the absolute and percentage changes from baseline, in COPD patients
(91.7  12.5 mL vs. 141.6  15.1 mL, p Z 0.01 and 8.3  1.2% vs. 13.4  1.4%, p Z 0.006).
Conclusion: A strong correlation between the EPHX1 113 mutant homozygote and smoking-
related COPD was noted. This genetic polymorphism was also associated with lower BDRs in
COPD patients.
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1cause of morbidity and mortality throughout the world, and
further increases in its prevalence and mortality can be
predicted in the coming decades. The World Health Orga-
nization has predicted that it will be the third leading cause
of death in the world by the year 2020.1 However, there are
still no effective drug therapies for COPD that alter disease
progression. Genetic studies of COPD have provided a new
approach to monitor disease with disease onset and disease
progression, define disease subtypes, and predict responses
to therapy. Genetic information may be used to develop
more target drugs and finally may lead to new treatments.2
Genetic association studies have implicated a variety of
genes in COPD pathogenesis, such as tumor necrosis factor-
a, glutathione S-transferase, and epoxide hydrolase (EPHX)
1 for COPD patients in Taiwan.3,4
Microsomal epoxide hydrolase (mEPHX) is an important
enzyme that metabolizes harmful reactive epoxides from
smoking. Genetic variations of this enzyme, including the
His113/His113 mEPHX exon-3 mutation (EPHX1 113 mutant
homozygote), are thought to increase the risk of developing
COPD.5e7 The current problem in studies of genetic poly-
morphism of EPHX1 in COPD is the different results from
various studies.5e10 These may occur because of the
phenotype definitions used or ethnic differences. A
systematic review and meta-analysis of the published data
may afford us a powerful tool to elucidate this association.
However, two recent meta-analyses showed opposite
results for the EPHX1 113 mutant homozygote in COPD. One
reported it had a protective effect with an odds ratio (OR)
of 0.5,11 and the other reported it was a risk factor with an
OR Z 1.59.12 These inconsistent results mean that more
studies of the association between this genetic variation
and COPD are necessary to clarify its role in COPD patients.
In the present study, the relationship between the EPHX1
113 mutant homozygote and susceptibility to COPD was
investigated.
In COPD patients, the bronchodilator response (BDR) has
been proposed to predict the survival and the annual rate
of decline of lung function.13e17 There is some evidence
that oxidative stress may contribute to reversible airway
narrowing.18,19 EPHX1 is an antioxidant-related gene,20 and
a recent study has found an association of BDR and EPHX1
gene polymorphism at amino acid position 622.21 To repli-
cate this finding for the role of EPHX1 in BDR in additional
populations, we studied the association between the EPHX1
113 mutant homozygote and the reversibility of airflow
obstruction (the BDR) in this study.Methods
Study population
This study was a hospital-based caseecontrol study that
consisted of 208 patients. The case group included 105 male
adults (age  40 years) with smoking-related COPD; most of
these patients visited National Cheng-Kung University
Hospital for their chronic airway symptoms such as cough-
ing and breathlessness. They were diagnosed as having
COPD on the basis of medical history, chest radiography,
and spirometry, according to the World Health Organization(GOLD) guidelines. Case group patients had a smoking
history of 10 pack-years, with chronic airway obstruction,
defined as a post-bronchodilator ratio of forced expiratory
volume in one second (FEV1)/forced vital capacity
(FVC) < 70%. Subjects were excluded if they had a history
of asthma. The control group included 103 smokers or
ex-smokers who were male adults (age  40 years with
a smoking history of 10 pack-years) without airway
obstruction demonstrated by spirometry as a ratio of FEV1/
FVC  70%. Most of the subjects visited our hospital for
health checkups. Only male patients were enrolled in this
study, because our hospital had few female smokers or
COPD patients. The study was approved by the Ethics
Committee of National Cheng-Kung University Medical
Collage and Hospital, and signed informed consent was
obtained from all patients.
DNA preparation
Genomic DNA was isolated from total blood cells by
Puregene commercial DNA isolation kits (Gentra Systems,
Minneapolis, MN, USA). Genomic DNA (20 ng) was amplified
by polymerase chain reaction (PCR). The PCR was per-
formed in a volume of 40 mL reaction mixture containing
1.5 mM MgCl2, 100 ng primer, 500 mM dNTP and 0.6 IU Taq
DNA polymerase (GeneMark, Taiwan). The amplification
protocol was done using a DNA Thermal Cycler (GeneAmp
PCR system 9700; Perkin Elmer Applied Biosystems,
Norwalk, CT, USA).
PCR restriction fragment length polymorphism
analysis of mEPHX gene
The polymorphism of mEPHX at exon 3 (EPHX1 113) was
determined by PCR and restriction fragment length poly-
morphism. The PCR conditions consisted of an initial single
cycle of 10 minutes at 94C, followed by 40 cycles of 94C
for 45 seconds, 52C for 20 seconds and 72C for 5 seconds.
For the PCR-based genotyping assays for mEPHX (exon 3),
the primer pair was synthesized with sense: 50-GATCGATA
AGTTCCGTTTCACC-30 and antisense: 50-ATCCTTAGTCTT
GAAGTGAGGAT-30. The PCR product was digested to
completion with Escherichia coli J62 pLG74 RV (New
England Biolabs, Beverly, MA, USA), and separated by
electrophoresis through a 3% agarose gel, stained with
ethidium bromide and transilluminated with ultraviolet
light. The exon-3 wild type allele was expected to yield 140
and 22 base pair fragments, and the mutation allele
revealed a 162 base pair fragment.
Pulmonary function tests
The procedures for spirometry have been previously
described in detail.22 Spirometry was performed before and
30 minutes after bronchodilator therapy with salbutamol
(400 mg). Patients were asked to omit short-acting bron-
chodilators for 8 hours and long-acting bronchodilators for
12 hours before testing. The BDR was expressed by two
common indexes (absolute and relative BDRs) used in clin-
ical practice. The absolute BDR was calculated as the
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bronchodilator and postbronchodilator values (post-
bronchodilator FEV1 e prebronchodilator FEV1), and the
relative BDR was calculated as a percentage of the pre-
bronchodilator value ([postbronchodilator FEV1 e pre-
bronchodilator FEV1]/ prebronchodilator FEV1)  100.
Statistical analysis
Associations between specific genotypes and phenotypes
were analyzed for significance by the two-tailed O2 test
and unpaired t test for univariate analysis. A logistic
regression model was used to calculate ORs adjusted for
age and cumulative cigarette consumption in pack-years
between smokers with and without COPD. Multivariate
analysis was used to assess the contributions of genetic
factors, age, smoking (status and cumulative amount by
pack-years) and baseline covariates (prebronchodilator
FEV1 for BDRs) to BDRs in COPD patients. We used the fit
model of standard least squares on the JMP software
program (SAS Institute Inc. Cary, NC, USA) doing multivar-
iate analysis. In each analysis, a difference with p < 0.05
was accepted as significant.Results
The characteristics of the control and COPD subjects are
summarized in Table 1. No significant differences were
observed in smoking history between the control and COPD
groups. The mean age was lower in the control group than
the COPD group; we adjusted for this incomplete matching
in the analysis of the data. The HardyeWeinberg equilib-
rium was used to test the genotypes in the control group
and no obvious deviation was found.
In the present study, subjects with the EPHX1 113
mutant homozygote (His113/His113) had a strong correlation
with COPD (OR: 2.7, 95% confidence interval: 1.5e5.2),
the frequency of this genotype was significantly higher inTable 1 Patient characteristics of COPD and control
smokers.
COPD
(n Z 105)
Controls
(n Z 103)
P value
Age (yr) 69.4  1.1 60.0  1.1 <0.001
Smoking/
pack-years
43.0  2.2 37.5  2.2 0.07
FEV1 % pred 56.7  1.8 93.1  1.8 <0.001
FVC % pred 75.0  1.8 92.5  1.8 <0.001
FEV1/FVC 50.5  0.9 79.6  0.9 <0.001
Genotypes
His 113/His113 61/105 (58.1%) 36/103 (35.0%) 0.001
His 113/Tyr113 28/105 (26.7%) 43/103 (41.7%) 0.01
Tyr 113/Tyr113 16/105 (15.2%) 24/103 (23.3%) 0.29
Values are expressed in mean  standard error. COPDZ chronic
obstructive pulmonary disease; FEV1 Z forced expiratory
volume in one second; pred Z predicted; FVC Z forced vital
capacity.the COPD group than the control group [61/105 (58.1%) vs.
36/103 (35.0%), p Z 0.001) (Table 1).
We reported that the EPHX1 113 mutant homozygote
was associated with lower BDRs in COPD patients. COPD
patients with the His113 homozygote mutation (nZ 61) had
significantly lower BDRs (absolute and relative), as shown
by the absolute change and percentage change from
baseline, than COPD patients with other genotypes (nZ 44)
(91.7  12.5 mL vs. 141.6  15.1 mL, p Z 0.01 and
8.3  1.2% vs. 13.4  1.4%, p Z 0.006) (Table 2).Discussion
A genetic variation of EPHX1 is thought to increase the risk
of developing COPD and is significantly associated with
rapid decline in lung function and disease severity in COPD
patients, because of its effect in decreasing enzyme
activity.5e7,23e25 However, various studies of genetic poly-
morphism of EPHX1 in COPD have shown different
results.5e10 Different phenotype definitions used in these
studies may be one of the important reasons for different
results for the same genetic variation.2,12
In the present study, the new definition of COPD from
the GOLD 2006 guidelines1 was used to set up the inclusion
criteria for our study group. According to the new guide-
lines, postbronchodilator FEV1/FVC and FEV1 measure-
ments are recommended for the diagnosis and assessment
of severity of COPD. The degree of reversibility of airflow
limitation, such as a significantly increased FEV1 after
bronchodilator, is no longer recommended for the diagnosis
or to differentiate COPD from asthma. This is because there
is increasing evidence that up to 30% of COPD patients with
non-fully reversible airway limitation have significant BDR
following administration of a short-acting b2 agonist (posi-
tive BDR).14 There were 34 COPD patients (34/105, 32.4%)
with significant BDR (relative BDR > 12% or absolute BDR
>200 mL) in our study; none of these patients had a history
or an established diagnosis of asthma. However, most
previous studies have excluded patients with significant
BDRs from their study group3,8e10,20; however, studies with
this exclusion criterion miss many COPD patients with BDR
phenotypes, which may cause varying results. In addition,
phenotype definition is a crucial issue for genetic investi-
gations of complex human diseases such as COPD. One
genome-wide study has suggested that postbronchodilator
spirometric measures are optimal phenotypes for COPD
genetic studies because they appear to provide more
powerful phenotypes (nearly doubled) for genetic studies
of COPD than conventional prebronchodilator spiromtery.26
However, postbronchodilator spirometry has been used in
only a few COPD genetic studies. Other than the present,
only one previous study11 has used GOLD guidelines with
postbronchodilator spirometry to analyze the association
between the EPHX1 and COPD phenotypes.
Our result is consistent with a recent meta-analysis
that has reported that the EPHX1 113 mutant homozygote
is significantly associated with an increased risk of COPD
(OR: 1.57, 95% confidence interval: 1.24e1.98) in Asian
populations.12
In COPD patients, a lower reversibility of airflow limi-
tation (lower BDR) is related to more severe emphysema27
Table 2 Comparison of EPHX1 genotypes with BDRs in COPD patients.
His113/His113 (n Z 61) His113/Tyr113 and
Tyr113/Tyr113 (n Z 44)
P value
Age 68.3  1.4 71.0  1.7 0.23
Smoking/pack-years 43.1  3.1 43.0  3.7 0.97
FVC (% pred) 75.3  2.5 74.6  3.0 0.80
FEV1 (% pred) 55.0  2.7 59.0  3.2 0.30
FEV1/FVC 49.7  1.5 51.6  1.7 0.41
Absolute BDR (mL) 91.7  12.5 141.6  15.1 0.01
Relative BDR (%) 8.3  1.2 13.4  1.4 0.006
Values are expressed in mean  standard error. EPHX Z epoxide hydrolase; BDR Z bronchodilator response; COPD Z chronic
obstructive pulmonary disease; FVC Z forced vital capacity; pred Z predicted; FEV1 Z forced expiratory volume in one second.
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survival.13,14 In addition, reversibility of airflow limitation is
also associated with airway eosinophils and predicts the
clinical and functional responses to inhaled corticosteroids
in COPD patients.28,29 Therefore, BDR may be a useful
indicator not only for predicting the clinical outcome and
survival but also identifying patients who respond to phar-
macological treatment. The precise mechanisms underlying
the reversibility of airflow limitation in COPD are still
debated; genetic study of COPD phenotypes may provide
opportunities to understand disease mechanisms. However,
there have been few genetic studies of BDR phenotypes in
COPD patients.2 In the present study, we reported that the
EPHX1 113 mutant homozygote was significantly associated
with a decreased BDR in COPD patients, as shown by the
absolute and percentage changes from baseline
(91.7  12.5 mL vs. 141.6  15.1 mL, p Z 0.01; and
8.3  1.2% vs. 13.4  1.4%, p Z 0.006). Our data suggest
a possible involvement of oxidative stress mechanisms in
the pathogenesis of BDR in COPD.
One limitation of the present study was that only male
adults were enrolled. The major population of COPD and
chronic smokers in our population is male, especially in
Southern Taiwan (<10% of recorded COPD patients and
chronic smokers in our hospital were female). Another
limitation is that this was a caseecontrol study with
a relatively small number of recruited subjects.
In conclusion, in our population, a strong correlation
between the EPHX1 113 mutant homozygote and smoking-
related COPD was noted, and this genetic polymorphism
was also associated with decreased BDR in COPD patients.Acknowledgments
This study was support by grant NSC 95-2314-B-006-026.
None of the authors has any financial interests related to
the material in the manuscript.References
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD).
Global strategy for the diagnosis, management, and prevention
of chronic obstructive pulmonary disease, 2005 updated.
Bethesda, MD: National Heart, Lung and Blood Institute/World
Health Organization; 2006.2. Molfino NA. Genetics of COPD: impact of basic research on
tomorrow’s medicine. Chest 2004;125:1929e40.
3. Cheng SL, Yu CJ, Chen CJ, Yang PC. Genetic polymorphism of
epoxide hydrolase and glutathione S-transferase in COPD. Eur
Respir J 2004;23:818e24.
4. Huang SL, Su CH, Chang SC. Tumor necrosis factor-a gene
polymorphism in chronic bronchitis. Am J Respir Crit Care Med
1997;156:1436e9.
5. Smith CA, Harrison DJ. Association between polymorphism in
gene for microsomal epoxide hydrolase and susceptibility to
emphysema. Lancet 1997;350:630e3.
6. Sandford AJ, Chagani T, Weir TD, Connett JE, Anthonisen NR,
Pare´ PD. Susceptibility genes for rapid decline of lung function
in the lung health study. Am J Respir Crit Care Med 2001;163:
469e73.
7. Demeo DL, Hersh CP, Hoffman EA, Litonjua AA, Lazarus R,
Sparrow D, et al. Genetic determinants of emphysema distri-
bution in the National emphysema treatment trial. Am J Respir
Crit Care Med 2007;176:42e8.
8. Takeyabu K, Yamaguchi E, Suzuki I, Nishimura M, Hizawa N,
Kamakami Y. Gene polymorphism for microsomal epoxide
hydrolase and susceptibility to emphysema in a Japanese
population. Eur Respir J 2000;15:891e4.
9. Yim JJ, Park GY, Lee CT, Kim YW, Han SK, Shim YS, et al. Gene
susceptibility to chronic obstructive pulmonary disease in
Koreans: combined analysis of polymorphic genotypes for
microsomal epoxide hydrolase and glutathione S-transferase
M1 and T1. Thorax 2000;55:121e5.
10. Chappell S, Daly L, Morgan K, Guetta-Baranes T, Roca J,
Rabinovich R, et al. Genetic variants of microsomal epoxide
hydrolase and glutamate-cysteine ligase in COPD. Eur Respir J
2008;32:931e7.
11. Brogger J, Steen VM, Eiken HG, Gulsvk A, Bakke P. Genetic
association between COPD and polymorphisms in TNF, ADRB2,
and EPHX1. Eur Respir J 2006;27:682e8.
12. Hu G, Shi Z, Hu J, Zou G, Peng G, Ran P. Association between
polymorphisms of microsomal epoxide hydrolase and COPD:
results from meta-analyses. Respirology 2008;13:837e50.
13. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic
obstructive pulmonary disease. Am Rev Respir Dis 1986;133:
14e20.
14. Anthonisen NR, Wright EC. Bronchodilator response in chronic
obstructive pulmonary disease. Am Rev Respir Dis 1986;133:
814e9.
15. Postma DS, Sluiter HJ. Prognosis of chronic obstructive
pulmonary disease: the Dutch experience. Am Rev Respir Dis
1989;140:S100e5.
16. Hansen EF, Phanareth K, Laursen LC, Kok-Jensen A, Dirksen A.
Reversible and irreversible airflow obstruction as predictor of
overall mortality in asthma and chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 1999;159:1267e71.
Epoxide hydrolase polymorphism in COPD 68917. Postma DS, Gimeno F, van der Weele LT, Sluiter HJ. Assessment
of ventilatory variables in survival prediction of patients with
chronic airflow obstruction: the importance of reversibility.
Eur J Respir Dis 1985;67:360e8.
18. Kawikova I, Barnes PJ, Takahashi T, Tadjkarimi S, Yacoub MH,
Belvisi MG. 8-Epi-PGF2 alpha, a novel noncyclooxygenase-
derived prostaglandin, constricts airways. in vitro. Am J
Respir Crit Care Med 1996;153:590e6.
19. Park HS, Kim SR, Lee YC. Impact of oxidative stress on lung
diseases. Respirology 2009;14:27e38.
20. Vibhuti A, Arif E, Deepak D, Singh B, Pasha MAQ. Genetic
polymorphisms of GSTP1 and mEPHX correlated with oxidative
stress markers and lung function in COPD. Biochem Biophys Res
Commun 2007;359:136e42.
21. Kim WJ, Hersh CP, DeMeo DL, Reilly JL, Silverman EK. Genetic
association analysis of COPD candidate genes with bronchodi-
lator responsiveness. Respir Med 2009;103:552e7.
22. Chen CZ, Lin CC, Li CH, Chang HY, Hsiue TR. Small airways
obstruction syndrome in clinical practice. Respirology 2009;
14:393e8.
23. Hersh CP, DeMeo DL, Silverman EK. National emphysema
treatment trial state of the art: genetics of emphysema. Proc
Am Thoracic Soc 2008;5:486e93.
24. Hassett C, Aicher L, Siduh JS, Omiecinski JC. Human micro-
somal epoxide hydrolase: genetic polymorphism and functionalexpression in vitro of amino acid variants. Hum Mol Genet
1994;3:421e8.
25. Hersh CP, DeMeo DL, Lazarus R, Celedo´n JC, Raby BA,
Benditt JO, et al. Genetic association analysis of functional
impairment in chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2006;173:977e84.
26. Palmer LJ, Celedon JC, Chapman HA, Speizer FE, Weiss ST,
Silverman EK. Genome-wide linkage analysis of bronchodilator
responsiveness and post-bronchodilator spirometric pheno-
types in chronic obstructive pulmonary disease. Hum Mol
Genet 2003;12:1199e210.
27. Schermer T, Heijdra Y, Zadel S, Bemt L, Winter LB,
Dekhuijzen R, et al. Flow and volume responses after routine
salbutamol reversibility testing in mild to very severe COPD.
Respir Med 2007;101:1355e62.
28. Kerstjens HA, Brand PL, Hughes MD, Robinson NJ, Postma DS,
Sluiter HJ, et al. A comparison of bronchodilator therapy with
or without inhaled corticosteroid therapy for obstructive
airways disease: Dutch chronic non-specific lung disease study
group. N Engl J Med 1992;327:1413e9.
29. Papi A, Romagnoli M, Baraldo S, Braccioni F, Guzzinati I,
Saetta M, et al. Partial reversibility of airflow limitation and
increased exhaled NO and sputum eosinophilia in chronic
obstructive pulmonary disease. Am J Respir Crit Care Med
2000;162:1773e7.
